Ondansetron ODF

Discover who we are and our partners global network, as well as learn more about our people.

Learn more about our products and how they provide innovative solutions for patiens' unmet needs.

Discover our capabilities in project design services.

Find information such as website news, press releases and event presentations.

Get in touch with us to set up a meeting or propose your cooperation.

ONDANSETRON ODF

ODF
technology

Ondansetron is indicated for the prevention and treatment of chemo- and radiotherapy induced nausea and vomiting (CINV and RINV), and for the prevention and treatment of post-operative nausea and vomiting (PONV).

Has been Developed by APR in cooperation with MonoSol Rx for the USA market and Labtec TESA outside USA respectively. The ODF technology aims to GET around administration problems of the drug and improve patient compliance.

* SETOFILM and the SETOFILM logo are registered trademarks of APR Applied Pharma s.a., exclusively licensed to the Norgine group of companies in the EU.

Ondissolve ODF logo is a registered trademark of Takeda Canada, exclusively licensed in Canada.

Zuplenz logo is a registered trademark of Galena Biopharma inc, exclusively licensed in USA.

* SETOFILM and the SETOFILM logo are registered trademarks of APR Applied Pharma s.a., exclusively licensed to the Norgine group of companies in the EU.

Nausea and Vomiting

Ondansetron
4mg and 8mg

Ultra-thin, oral dissolvable film, composed of a water-soluble polymer, used to administer therapeutic agents in a wide range of indications.

Film dissolves on the tongue within seconds (liquid not required). Gastrointestinal absorption comparable to immediate release, oral solid dosage forms.

Advantages of ODF:

Ease of administration.

Can be used in patients who have difficulties
swallowing (elderly and young children).

No liquid necessary.

Film cannot be spat out.

No risk of aspiration.

Easy to take when out of home/travelling.

Ondansetron ODF (4 and 8 mg)

Ondansetron OroDispersible Film/Orally Disintegrating Film (ODF), designed to improve patient compliance, has a number of important advantages over conventional forms of ondansetron:

Higher compliance compared with Zofran® tablets - swallowing is easy and water is not required.

Higher compliance compared with Zofran® syrup - fluid intake not necessary, no strawberry taste in the mouth, improved dosing accuracy, and shorter handling times.

Higher compliance compared with Zofran® OroDispersible tablets/orally disintegrating tablets (ODT) - easier to handle and store.

The absence of aspartame in the formulation makes the product suitable for phenylketonuric patients, for whom the use of ondansetron Zofran® ODT is contraindicated.

Diclofenac Immediate Release		APR TD011 – Epidermolysis Bullosa